SHB (SH2 domain containing adaptor protein B) is a signal transduction adapter protein that mediates multiple signaling cascades. The protein functions through its SH2 domain to link activated cell surface receptors to downstream effectors 1. Mechanistically, SHB associates with receptor tyrosine kinases and adaptor complexes to facilitate signal propagation. Notably, SHB interacts with SLAMF7 through tyrosine-304-mediated binding to recruit SHIP1, which inhibits TRAF6 ubiquitination and suppresses MAPK pathway activation 1. In acute myeloid leukemia (AML), SHB expression levels significantly impact disease characteristics and patient survival. Tumors overexpressing SHB mRNA show reduced survival compared to low-expressing cases, and SHB knockdown impairs leukemic cell proliferation in APL and monocytic cell lines 2. SHB forms a co-regulatory network with PAX5, HDAC7, BCORL1, and TET1 that influences AML phenotypes including immune cell infiltration, vascular properties, and apoptotic features 2. The clinical significance of SHB extends to immunotherapy responsiveness in hepatocellular carcinoma, where SLAMF7-SHB signaling regulates macrophage polarization through CCL2 suppression, affecting checkpoint inhibitor efficacy 1. These findings suggest SHB represents a potential therapeutic target in hematologic and hepatic malignancies.